Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.

Literature DB >> 15917556

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.

Edmund V Capparelli¹, Scott L Letendre, Ronald J Ellis, Parul Patel, Diane Holland, J Allen McCutchan.

Abstract

The distribution of abacavir into the cerebrospinal fluid (CSF) was assessed by use of a population pharmacokinetic analysis. Plasma and CSF abacavir concentrations in 54 subjects were determined. The abacavir CSF/plasma ratio averaged 36% and increased throughout the dose interval. Abacavir penetrates into the CSF in adequate concentrations to inhibit local human immunodeficiency virus replication.

Entities: Chemical Species

Mesh：

Substances：

Year: 2005 PMID： 15917556 PMCID： PMC1140502 DOI： 10.1128/AAC.49.6.2504-2506.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

1. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

Authors: R M van Praag; R P van Heeswijk; S Jurriaans; J M Lange; R M Hoetelmans; J M Prins
Journal: Clin Infect Dis Date: 2001-09-20 Impact factor: 9.079

2. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.

Authors: N A Foudraine; R M Hoetelmans; J M Lange; F de Wolf; B H van Benthem; J J Maas; I P Keet; P Portegies
Journal: Lancet Date: 1998-05-23 Impact factor: 79.321

3. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors: S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal: Antimicrob Agents Chemother Date: 1997-05 Impact factor: 5.191

4. Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man.

Authors: R Nau; G Zysk; A Thiel; H W Prange
Journal: Eur J Clin Pharmacol Date: 1993 Impact factor: 2.953

Review 5. Penetration of newer cephalosporins into cerebrospinal fluid.

Authors: C E Cherubin; R H Eng; R Norrby; J Modai; G Humbert; G Overturf
Journal: Rev Infect Dis Date: 1989 Jul-Aug

Review 6. Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy.

Authors: D M Simpson
Journal: Clin Infect Dis Date: 1999-07 Impact factor: 9.079

7. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.

Authors: J A McDowell; Y Lou; W S Symonds; D S Stein
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

8. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

Authors: S Weller; K M Radomski; Y Lou; D S Stein
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

Review 9. Antibiotic pharmacodynamics in cerebrospinal fluid.

Authors: I Lutsar; G H McCracken; I R Friedland
Journal: Clin Infect Dis Date: 1998-11 Impact factor: 9.079

10. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.

Authors: J A McDowell; G E Chittick; J R Ravitch; R E Polk; T M Kerkering; D S Stein
Journal: Antimicrob Agents Chemother Date: 1999-12 Impact factor: 5.191

20 in total

1. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

Authors: David Croteau; Scott Letendre; Brookie M Best; Ronald J Ellis; Sheila Breidinger; David Clifford; Ann Collier; Benjamin Gelman; Christina Marra; Gilbert Mbeo; Allen McCutchan; Susan Morgello; David Simpson; Lauren Way; Florin Vaida; Susan Ueland; Edmund Capparelli; Igor Grant
Journal: Antimicrob Agents Chemother Date: 2010-09-27 Impact factor: 5.191

2. Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Authors: Eric H Decloedt; Bernd Rosenkranz; Gary Maartens; John Joska
Journal: Clin Pharmacokinet Date: 2015-06 Impact factor: 6.447

3. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.

Authors: Brookie M Best; Scott L Letendre; Peter Koopmans; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David M Simpson; Edmund V Capparelli; Ronald J Ellis; Igor Grant
Journal: J Acquir Immune Defic Syndr Date: 2012-04-01 Impact factor: 3.731

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.

1. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

2. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.

3. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

4. Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man.

Review 5. Penetration of newer cephalosporins into cerebrospinal fluid.

Review 6. Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy.

7. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.

8. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

Review 9. Antibiotic pharmacodynamics in cerebrospinal fluid.

10. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.

1. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

2. Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

3. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.

Review 4. Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Review 5. CSF penetration by antiretroviral drugs.

6. Cell-cell contact viral transfer contributes to HIV infection and persistence in astrocytes.

7. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration.

Review 8. Pharmacologic approaches to HIV-associated neurocognitive disorders.

Review 9. A review of the pharmacokinetics of abacavir.

Review 10. Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.